These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 18317064

  • 1. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V, Major PP, Lipton A, Cook RJ, Langer CJ, Smith MR, Brown JE, Coleman RE.
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [Abstract] [Full Text] [Related]

  • 2. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A, Cook R, Brown J, Body JJ, Smith M, Coleman R.
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A, Cook RJ, Major P, Smith MR, Coleman RE.
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [Abstract] [Full Text] [Related]

  • 4. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE.
    Cancer; 2008 Jul 01; 113(1):193-201. PubMed ID: 18459173
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY, Zou QF, Jin C, Li WD, Chen WS, Ma L.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun 01; 30(6):1343-6. PubMed ID: 20584674
    [Abstract] [Full Text] [Related]

  • 6. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
    Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK.
    Int J Cancer; 2009 Oct 01; 125(7):1705-9. PubMed ID: 19521984
    [Abstract] [Full Text] [Related]

  • 7. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.
    J Natl Cancer Inst; 2005 Jan 05; 97(1):59-69. PubMed ID: 15632381
    [Abstract] [Full Text] [Related]

  • 8. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R.
    Int J Clin Oncol; 2011 Jun 05; 16(3):264-9. PubMed ID: 21240683
    [Abstract] [Full Text] [Related]

  • 9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 05; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 10. N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases.
    Kaira R, Murakami H, Kaira K, Takahashi T, Tsuya A, Nakamura Y, Naito T, Endo M, Yamamoto N.
    Int J Clin Oncol; 2010 Oct 05; 15(5):484-8. PubMed ID: 20556457
    [Abstract] [Full Text] [Related]

  • 11. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
    Saad F, Segal S, Eastham J.
    Eur Urol; 2014 Jan 05; 65(1):146-53. PubMed ID: 22633317
    [Abstract] [Full Text] [Related]

  • 12. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 05; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 13. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid.
    Zhao X, Xu X, Zhang Q, Jia Z, Sun S, Zhang J, Wang B, Wang Z, Hu X.
    BMC Cancer; 2011 Sep 22; 11():403. PubMed ID: 21936956
    [Abstract] [Full Text] [Related]

  • 14. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J, TUGAMO GROUP.
    Br J Cancer; 2013 Jul 09; 109(1):121-30. PubMed ID: 23799855
    [Abstract] [Full Text] [Related]

  • 15. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
    Orita Y, Sugitani I, Takao S, Toda K, Manabe J, Miyata S.
    Ann Surg Oncol; 2015 Nov 09; 22(12):4008-13. PubMed ID: 25762482
    [Abstract] [Full Text] [Related]

  • 16. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
    Langer C, Hirsh V.
    Lung Cancer; 2010 Jan 09; 67(1):4-11. PubMed ID: 19939491
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom.
    Botteman MF, Meijboom M, Foley I, Stephens JM, Chen YM, Kaura S.
    Eur J Health Econ; 2011 Dec 09; 12(6):575-88. PubMed ID: 20809091
    [Abstract] [Full Text] [Related]

  • 18. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May 09; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 19. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Miyoshi Y.
    Breast Cancer; 2017 Mar 09; 24(2):245-253. PubMed ID: 27040403
    [Abstract] [Full Text] [Related]

  • 20. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
    Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, Hadala JT, Warsi G, Argonza-Aviles E, Ericson SG, Anderson KC.
    Clin Cancer Res; 2016 Mar 15; 22(6):1378-84. PubMed ID: 26644410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.